{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:15:50Z","timestamp":1791353750691,"version":"4.3.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"French Association for Cancer Research","award":["ECL2010R00778"],"award-info":[{"award-number":["ECL2010R00778"]}]},{"name":"Liddy Shriver Sarcoma Initiative"},{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"crossref","award":["INCa-6001"],"award-info":[{"award-number":["INCa-6001"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["thebonejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.bone.2014.12.011","type":"journal-article","created":{"date-parts":[[2014,12,20]],"date-time":"2014-12-20T05:59:47Z","timestamp":1419055187000},"page":"51-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: Mouse strain disparities and synergic effect with zoledronic acid"],"prefix":"10.1016","volume":"73","author":[{"given":"Fr\u00e9d\u00e9ric","family":"L\u00e9zot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Chesneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Navet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9reng\u00e8re","family":"Gobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9rome","family":"Amiaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YongWon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yagita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Castaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Berdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"R\u00e9dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Heymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2014.12.011_bb0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1749-6632.2010.05769.x","article-title":"Bisphosphonate use in conditions other than osteoporosis","volume":"1218","author":"Silverman","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bone.2014.12.011_bb0010","article-title":"Prevention and treatment of postmenopausal osteoporosis","author":"Tella","year":"2013","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.bone.2014.12.011_bb0015","first-page":"2981","article-title":"Antineoplastic activity of zoledronic acid and denosumab","volume":"33","author":"Zwolak","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bone.2014.12.011_bb0020","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1600-0412.2012.01473.x","article-title":"New developments in the treatment of osteoporosis","volume":"92","author":"Eriksen","year":"2013","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.bone.2014.12.011_bb0025","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrrheum.2011.181","article-title":"Epidemiology and pathogenesis of osteonecrosis of the jaw","volume":"8","author":"Reid","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bone.2014.12.011_bb0030","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1515\/jpem-2012-0016","article-title":"Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta","volume":"25","author":"Barros","year":"2012","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.12.011_bb0035","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2014.12.011_bb0040","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(13)61531-7","article-title":"Oral bisphosphonates for paediatric osteogenesis imperfecta?","volume":"382","author":"Ward","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2014.12.011_bb0045","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/BPO.0b013e3182a006a0","article-title":"Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy","volume":"34","author":"Sousa","year":"2014","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.bone.2014.12.011_bb0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1515\/JPEM.2000.13.2.217","article-title":"Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia","volume":"13","author":"Demir","year":"2000","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.12.011_bb0055","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1359\/jbmr.040127","article-title":"Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy","volume":"19","author":"Cundy","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.12.011_bb0060","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00774-010-0198-8","article-title":"Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease","volume":"28","author":"Polyzos","year":"2010","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.bone.2014.12.011_bb0065","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/jbmr.1868","article-title":"Juvenile paget's disease in an Iranian kindred with vitamin D deficiency and novel homozygous TNFRSF11B mutation","volume":"28","author":"Saki","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.12.011_bb0070","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.ejca.2013.03.018","article-title":"Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group","volume":"49","author":"Goldsby","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bone.2014.12.011_bb0075","first-page":"183","article-title":"First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI","volume":"12","author":"Semler","year":"2012","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.bone.2014.12.011_bb0080","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","article-title":"Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study","volume":"14","author":"Chawla","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bone.2014.12.011_bb0085","article-title":"Golden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone","author":"Demirsoy","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.bone.2014.12.011_bb0090","article-title":"Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets","author":"Federman","year":"2013","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.bone.2014.12.011_bb0095","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1200\/JCO.2012.46.4255","article-title":"Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl","volume":"31","author":"Karras","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bone.2014.12.011_bb0100","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1210\/jc.2013-1143","article-title":"Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease","volume":"98","author":"Grasemann","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.12.011_bb0105","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00586-013-2715-7","article-title":"Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts","volume":"22","author":"Lange","year":"2013","journal-title":"Eur Spine J"},{"key":"10.1016\/j.bone.2014.12.011_bb0110","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.12.011_bb0115","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/jbmr.453","article-title":"Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient","volume":"26","author":"Battaglia","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.12.011_bb0120","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bone.2014.08.018","article-title":"Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies","volume":"68","author":"L\u00e9zot","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2014.12.011_bb0125","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1196\/annals.1346.041","article-title":"Bisphosphonates: from bench to bedside","volume":"1068","author":"Russell","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bone.2014.12.011_bb0130","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.bone.2014.12.011_bb0135","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1084\/jem.192.10.1467","article-title":"Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE","volume":"192","author":"Kim","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.bone.2014.12.011_bb0140","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/pr.2012.118","article-title":"High- and low-dose OPG-Fc cause osteopetrosis-like changes in infant mice","volume":"72","author":"Bargman","year":"2012","journal-title":"Pediatr Res"},{"key":"10.1016\/j.bone.2014.12.011_bb0145","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/SCS.0b013e3182077fbd","article-title":"Role of RANK\u2013RANKL-OPG axis in cranial suture homeostasis","volume":"22","author":"Lee","year":"2011","journal-title":"J Craniofac Surg"},{"key":"10.1016\/j.bone.2014.12.011_bb0150","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jcp.22305","article-title":"Bone resorption control of tooth eruption and root morphogenesis: involvement of the receptor activator of NF-\u03baB (RANK)","volume":"226","author":"Castaneda","year":"2011","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.bone.2014.12.011_bb0155","doi-asserted-by":"crossref","first-page":"e80054","DOI":"10.1371\/journal.pone.0080054","article-title":"Role of RANKL (TNFSF11)-dependent osteopetrosis in the dental phenotype of Msx2 null mutant mice","volume":"8","author":"Castaneda","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2014.12.011_bb0160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2014.12.011_bb0165","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.bone.2014.12.011_bb0170","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1582-4934.2008.00141.x","article-title":"Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells","volume":"12","author":"Ory","year":"2008","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.bone.2014.12.011_bb0175","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1586\/era.09.7","article-title":"Novel therapeutic agents for osteosarcoma","volume":"9","author":"O'Day","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.bone.2014.12.011_bb0180","first-page":"3565","article-title":"Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid","volume":"30","author":"Morii","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bone.2014.12.011_bb0185","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bone.2005.02.020","article-title":"Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma","volume":"37","author":"Heymann","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2014.12.011_bb0190","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/cncr.21383","article-title":"Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma","volume":"104","author":"Zhou","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2014.12.011_bb0195","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/jor.20129","article-title":"Anticancer effects of zoledronic acid against human osteosarcoma cells","volume":"24","author":"Kubista","year":"2006","journal-title":"J Orthop Res"},{"key":"10.1016\/j.bone.2014.12.011_bb0200","first-page":"285","article-title":"Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM\/Chk1\/cdc25 pathway in human osteosarcoma cells","volume":"31","author":"Iguchi","year":"2007","journal-title":"Int J Oncol"},{"key":"10.1016\/j.bone.2014.12.011_bb0205","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1158\/1078-0432.CCR-08-1616","article-title":"Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model","volume":"15","author":"Labrinidis","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bone.2014.12.011_bb0210","doi-asserted-by":"crossref","first-page":"7610","DOI":"10.1158\/0008-5472.CAN-09-4272","article-title":"Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients","volume":"70","author":"Odri","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2014.12.011_bb0215","first-page":"499","article-title":"Effective salvage treatment of recurrent Ewing sarcoma utilizing chemotherapy and zoledronic acid","volume":"8","author":"Siddiqui","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.bone.2014.12.011_bb0220","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/j.jcms.2011.10.024","article-title":"The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells","volume":"40","author":"A\u00e7il","year":"2012","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.bone.2014.12.011_bb0225","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3892\/ol.2012.723","article-title":"Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells","volume":"4","author":"Chang","year":"2012","journal-title":"Oncol Lett"},{"key":"10.1016\/j.bone.2014.12.011_bb0230","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.canlet.2006.10.004","article-title":"Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells","volume":"250","author":"Benassi","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bone.2014.12.011_bb0235","doi-asserted-by":"crossref","first-page":"10329","DOI":"10.1158\/0008-5472.CAN-10-0578","article-title":"Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process","volume":"70","author":"Moriceau","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2014.12.011_bb0240","first-page":"233","article-title":"Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents","volume":"24","author":"Koto","year":"2010","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bone.2014.12.011_bb0245","first-page":"2713","article-title":"Combined effects of bisphosphonate and radiation on osteosarcoma cells","volume":"30","author":"Ryu","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bone.2014.12.011_bb0250","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/jor.21579","article-title":"Sensitization of human osteosarcoma cells to V\u03b39V\u03b42 T-cell-mediated cytotoxicity by zoledronate","volume":"30","author":"Li","year":"2012","journal-title":"J Orthop Res"},{"key":"10.1016\/j.bone.2014.12.011_bb0255","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3892\/or.2013.2907","article-title":"In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma","volume":"31","author":"Dos Santos","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bone.2014.12.011_bb0260","first-page":"261","article-title":"RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells","volume":"28","author":"Wittrant","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1016\/j.bone.2014.12.011_bb0265","first-page":"235","article-title":"Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells?","volume":"24","author":"Mori","year":"2009","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.bone.2014.12.011_bb0270","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/path.2140","article-title":"Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B","volume":"211","author":"Mori","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.bone.2014.12.011_bb0275","first-page":"1365","article-title":"Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells","volume":"18","author":"Mori","year":"2007","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bone.2014.12.011_bb0280","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.tripleo.2010.06.014","article-title":"Markers of bone remodeling in neoplastic and bone-related lesions","volume":"110","author":"Elias","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.bone.2014.12.011_bb0285","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1515\/bc.2010.149","article-title":"Physiology and pathophysiology of the RANKL\/RANK system","volume":"391","author":"Hanada","year":"2010","journal-title":"Biol Chem"},{"key":"10.1016\/j.bone.2014.12.011_bb0290","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-011-0749-z","article-title":"RANKL\/RANK-beyond bones","volume":"89","author":"Hanada","year":"2011","journal-title":"J Mol Med"},{"key":"10.1016\/j.bone.2014.12.011_bb0295","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nature08596","article-title":"Central control of fever and female body temperature by RANKL\/RANK","volume":"462","author":"Hanada","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bone.2014.12.011_bb0300","doi-asserted-by":"crossref","first-page":"120150","DOI":"10.1098\/rsob.120150","article-title":"Regulation of neurite growth by tumour necrosis superfamily member RANKL","volume":"3","author":"Gutierrez","year":"2013","journal-title":"Open Biol"},{"key":"10.1016\/j.bone.2014.12.011_bb0305","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bone.2014.12.011_bb0310","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.4049\/jimmunol.1101513","article-title":"RANKL induces organized lymph node growth by stromal cell proliferation","volume":"188","author":"Hess","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.bone.2014.12.011_bb0315","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fimmu.2012.00261","article-title":"Emerging functions of RANKL in lymphoid tissues","volume":"3","author":"Mueller","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.bone.2014.12.011_bb0320","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/intimm\/dxs002","article-title":"Expression pattern changes and function of RANKL during mouse lymph node microarchitecture development","volume":"24","author":"Sugiyama","year":"2012","journal-title":"Int Immunol"},{"key":"10.1016\/j.bone.2014.12.011_bb0325","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/nm1518","article-title":"Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells","volume":"12","author":"Loser","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.bone.2014.12.011_bb0330","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/nm1206-1358","article-title":"Skin controls immune regulators","volume":"12","author":"Yamaguchi","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.bone.2014.12.011_bb0335","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.4049\/jimmunol.181.2.1103","article-title":"Epidermal receptor activator of NF-kappaB ligand controls Langerhans cells numbers and proliferation","volume":"181","author":"Barbaroux","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.bone.2014.12.011_bb0340","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1073\/pnas.1013054108","article-title":"Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit","volume":"108","author":"Duheron","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bone.2014.12.011_bb0345","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-4419-1050-9_9","article-title":"Novel functions of RANK(L) signaling in the immune system","volume":"658","author":"Leibbrandt","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.bone.2014.12.011_bb0350","doi-asserted-by":"crossref","first-page":"142","DOI":"10.5312\/wjo.v3.i9.142","article-title":"RANKL\u2013RANK interaction in immune regulatory systems","volume":"3","author":"Akiyama","year":"2012","journal-title":"World J Orthop"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328214004633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328214004633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T13:08:16Z","timestamp":1566133696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328214004633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":70,"alternative-id":["S8756328214004633"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2014.12.011","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: Mouse strain disparities and synergic effect with zoledronic acid","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2014.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}